2024 IPO

Alto Neuroscience Stock

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Sign up today and learn more about Alto Neuroscience Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Alto Neuroscience Stock

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.

Funding History

September 2019$8.0M
May 2021$32.0M
October 2022$35.0M
January 2023$25.0M
January 2023$35.0M

Management

Chief Medical Officer

Adam Savitz

Vice President, Clinical Operations

Lesley Parker

Founder and CEO

Amit Etkin

Board Member

Christopher Cox

Board Observer

Robert Baloh

Chief Business Officer

Nick Smith

Board Member

Jeff Chen

Board Member

Chris Dimitropoulos

Co-Founder and Chief Data Science Officer

Wei Wu

Chief of Staff

Brooke Torres

Chief Operating Officer

Mikael Eliasson

Vice President, Drug Development

Bruce Morimoto

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo